Shandong Pharmaceutical Glass Co (SHSE:600529) Operating Income: ¥965 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600529 Shandong Pharmaceutical Glass Co Ltd SHSE:600529
93 GF Score
Price ¥19.18
GF Value ¥23.56
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Shandong Pharmaceutical Glass Co Operating Income?

Shandong Pharmaceutical Glass Co SHSE:600529 93 Operating Income is ¥965 Mil as of Jun. 2026. GuruFocus rates SHSE:600529 with a GF Score™ of 93/100 and a GF Value™ of ¥23.56 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Shandong Pharmaceutical Glass Co's Operating Income for the three months ended in Jun. 2026 was ¥218 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was ¥965 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Shandong Pharmaceutical Glass Co's Operating Income for the three months ended in Jun. 2026 was ¥218 Mil. Shandong Pharmaceutical Glass Co's Revenue for the three months ended in Jun. 2026 was ¥1,061 Mil. Therefore, Shandong Pharmaceutical Glass Co's Operating Margin % for the quarter that ended in Jun. 2026 was 20.52%.

Good Sign:

Shandong Pharmaceutical Glass Co Ltd operating margin is expanding. Margin expansion is usually a good sign.

Shandong Pharmaceutical Glass Co's 5-Year average Growth Rate for Operating Margin % was 1.90% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shandong Pharmaceutical Glass Co's annualized ROC % for the quarter that ended in Jun. 2026 was 11.70%. Shandong Pharmaceutical Glass Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 17.49%.


Shandong Pharmaceutical Glass Co  (SHSE:600529) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shandong Pharmaceutical Glass Co's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=871.112 * ( 1 - 20.39% )/( (5871.118 + 5979.401)/ 2 )
=693.4922632/5925.2595
=11.70 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10136.628 - 1524.291 - ( 2741.219 - max(0, 1611.973 - 6106.79+2741.219))
=5871.118

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10128.426 - 1365.968 - ( 2783.057 - max(0, 1440.133 - 6125.63+2783.057))
=5979.401

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Shandong Pharmaceutical Glass Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=852.056/( ( (3655.236 + max(1190.009, 0)) + (3585.873 + max(1312.436, 0)) )/ 2 )
=852.056/( ( 4845.245 + 4898.309 )/ 2 )
=852.056/4871.777
=17.49 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1008.968 + 1670.502 + 107.054) - (1524.291 + 0 + 72.224)
=1190.009

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(870.668 + 1733.801 + 131.471) - (1365.968 + 0 + 57.536)
=1312.436

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Shandong Pharmaceutical Glass Co's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=217.778/1061.331
=20.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Shandong Pharmaceutical Glass Co Operating Income Related Terms


Shandong Pharmaceutical Glass Co Operating Income Historical Data

* Premium members only.

The historical data trend for Shandong Pharmaceutical Glass Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Pharmaceutical Glass Co Operating Income Chart

Shandong Pharmaceutical Glass Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 732.18 707.23 898.90 1,100.64 946.52

Shandong Pharmaceutical Glass Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 209.96 225.90 252.49 268.83 217.78
SHSE:600529
93GF Score
Shandong Pharmaceutical Glass Co Ltd SHSE:600529
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Pharmaceutical Glass Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥965 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of ¥965 Mil mean?
Shandong Pharmaceutical Glass Co (SHSE:600529) has a Operating Income of ¥965 Mil as of Jun. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Shandong Pharmaceutical Glass Co and its competitors.
Is Shandong Pharmaceutical Glass Co's Operating Income too high?
Shandong Pharmaceutical Glass Co's current Operating Income is ¥965 Mil. Overall, Shandong Pharmaceutical Glass Co has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Pharmaceutical Glass Co's Operating Income compare to SW and AMCR?
Shandong Pharmaceutical Glass Co's Operating Income of ¥965 Mil can be compared against companies in the Packaging & Containers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Packaging & Containers company?
A good Operating Income depends on the Packaging & Containers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Shandong Pharmaceutical Glass Co and its competitors. Shandong Pharmaceutical Glass Co's current Operating Income is ¥965 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Pharmaceutical Glass Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Pharmaceutical Glass Co (SHSE:600529) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥23.56, compared to a current price of ¥19.18 — trading 18.6% below its estimated fair value. The current Operating Income is ¥965 Mil. Shandong Pharmaceutical Glass Co's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Shandong Pharmaceutical Glass Co (SHSE:600529), the current Operating Income is ¥965 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Pharmaceutical Glass Co (SHSE:600529) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Pharmaceutical Glass Co stock appears to be undervalued. The current stock price of ¥19.18 is trading 18.6% below its estimated GF Value™ of ¥23.56. GuruFocus considers Shandong Pharmaceutical Glass Co to be Modestly Undervalued.

Key valuation signals for SHSE:600529:

  • Operating Income: ¥965 Mil
  • GF Value™: ¥23.56 vs. price of ¥19.18 (18.6% below fair value)
  • GF Score™: 93/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600529 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shandong Pharmaceutical Glass Co Business Description

Address Yaobo Road, Yiyuan County, Zibo, Shandong, CHN, 256100
Shandong Pharmaceutical Glass Co Ltd is a pharmaceutical glass packaging product company. Its pharmaceutical glass packaging products and butyl rubber series products which service object of pharmaceutical, food, daily necessities industries. The products include for moulded injection vial for antibiotics series, tubular glass vial series, amber glass bottle series, neutral borosilicate glass bottle series, infusion bottle series, cosmetic bottles series, food bottles series, butyl rubber stopper series, prefillable syringes series, and aluminum-plastic cap series.
93GF Score

Get the complete analysis for SHSE:600529

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥19.18
Price
¥23.56
GF Value